Eli Lilly and Co. (NYSE:LLY) on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone for plaque psoriasis and obesity.
The study demonstrated the efficacy of its drugs Taltz and Zepbound in treating psoriasis and obesity.
27.1% of participants receiving Taltz and Zepbound reached complete skin clearance (Psoriasis Area Severity Index (PASI) 100) and at least 10% weight loss, compared to 5.8% of patients treated with Taltz alone, meeting the primary endpoint.
Taltz and Zepbound delivered a 40% relative increase over Taltz monotherapy in the proportion of patients who achieved PASI 100 (40.6% vs.29%).
Side Effects
The most common adverse events were nausea, diarrhea, constipation, injection site reaction, dosing error, vomiting, and dizziness in the Taltz and Zepbound concomitant treatment arm, and injection site reaction, dosing error, and nasopharyngitis in the Taltz monotherapy arm.
Agreement With Australian Company
CSL Limited (OTC:CSLLY) on Wednesday entered into an exclusive licensing agreement with Eli Lilly, granting certain rights to develop and commercialize clazakizumab.
CSL will receive an upfront payment of $100 million and be eligible to receive potential clinical, regulatory, and commercial milestone payments, as well as royalties on global net sales.
CSL will retain exclusive rights to develop and commercialize clazakizumab for the prevention of cardiovascular events in patients with end-stage kidney disease (ESKD). CSL is advancing the ongoing POSIBIL 6ESKD Phase 3 trial of clazakizumab.
Lilly will explore the development, global regulatory approval, and commercialisation of clazakizumab in additional indications.
Technical Analysis
The stock is currently trading 2.7% below its 20-day simple moving average (SMA) and 3.2% below its 50-day SMA, indicating short-term weakness. However, it remains 4.3% above its 100-day SMA and 17.6% above its 200-day SMA, suggesting longer-term strength.
The RSI is at 48.22, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, the MACD shows a value of -5.0984, below its signal line of -3.9365, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should be cautious in their positions.
- Key Resistance: $1088.50
- Key Support: $1012.50
Analyst Consensus & Recent Actions
Eli Lillystock carries a Buy Rating with an average price target of $1141.70. Recent analyst moves include:
- Deutsche Bank: Buy (Raises Target to $1285.00) (Feb. 9)
- JP Morgan: Overweight (Raises Target to $1300.00) (Feb. 5)
- Cantor Fitzgerald: Overweight (Raises Target to $1205.00) (Feb. 5)
Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for Eli Lilly, highlighting its strengths and weaknesses compared to the broader market:
- Value Rank: 3.49 — The stock is trading at a steep premium relative to peers.
- Quality Rank: 90.9 — The balance sheet remains healthy.
- Momentum Rank: 84.91 — Stock is outperforming the broader market.
The Verdict: Eli Lilly’s Benzinga Edge signal reveals a strong momentum score, indicating positive price action. However, the low value score suggests that investors should be cautious about the stock’s premium valuation relative to its peers.
LLY Price Action: Eli Lilly shares were down 1.62% at $1019.22 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo by Ciara Kimsey via Shutterstock
Recent Comments